DNA
Ginkgo Bioworks Holdings, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -21.4% ·
share flow +0.2% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +5 | 25.52M | $252.75M | +9 | −4 |
| Q1 2026 | 72 | -1 | 23.15M | $141.95M | +6 | −7 |
| Q4 2025 | 73 | +2 | 24.08M | $200.09M | +2 | — |
| Q3 2025 | 15 | -2 | 16.22M | $236.55M | — | −2 |
| Q2 2025 | 14 | 0 | 15.99M | $179.94M | +2 | −2 |
| Q1 2025 | 11 | -3 | 10.22M | $58.26M | — | −3 |
| Q4 2024 | 14 | +3 | 10.20M | $100.21M | +3 | — |
| Q3 2024 | 10 | -3 | 9.70M | $79.02M | — | −3 |
| Q2 2024 | 13 | — | 419.17M | $140.02M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 3.58M | 0.0% | $20.39M | 0.1% | Held | 4 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 3.35M | -0.2% | $19.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 3.35M | -0.2% | $19.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 3.35M | -0.2% | $19.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Baillie Gifford ✦ | 3.35M | -0.2% | $19.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Millennium Management ✦ | 1.43M | +113.0% | $8.14M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 458.43K | +4.9% | $2.61M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 458.43K | +4.9% | $2.61M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passive) | 335.37K | +40.4% | $1.91M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 314.22K | -51.3% | $1.79M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Marshall Wace ✦ | 263.74K | +289.7% | $1.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Marshall Wace ✦ | 263.74K | +289.7% | $1.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Glenview Capital ✦ | 187.50K | 0.0% | $1.07M | 0.0% | Held | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 158.94K | +322.6% | $905,953 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 158.94K | +322.6% | $905,953 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 158.94K | +322.6% | $905,953 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 158.94K | +322.6% | $905,953 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 158.94K | +322.6% | $905,953 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 74.28K | -10.3% | $424,000 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 74.28K | -10.3% | $424,000 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Point72 Asset Management ✦ | 73.10K | -26.8% | $416,670 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| D. E. Shaw & Co. | $5.37M | was 0.0% |
| Citadel Advisors | $1.39M | was 0.0% |
| Renaissance Technologies | $1.13M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 140 shares, $0 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 330 sh · $2,302
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology